CXCL1 and breast carcinoma: In addition, co-treatment of breast cancer cells with GroA and tyrphostin AG-825, a specific ErbB2 inhibitor17, has led to decreased cell viability, inhibition of ErbB2-mediated signaling, increased cell death and, most importantly, suppression of cell tumorigenicity.